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Purpose: We investigated the effect of epidermal growth factor receptor (EGFR) siRNA on human lens epithelium (HLE)
cells and the development of posterior capsular opacity (PCO).
Methods: We designed EGFR siRNA and used it to knockdown the expression of EGFR in HLE cells. Cell proliferation
was examined by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), cell growth curve assay and cell
cycle analysis. Next, we selected an adaptable concentration of recombinant epidermal growth factor (EGF) for stimulating
the growth of HLE cells to further test the suppressive effect of siRNA. At last, we established the model of PCO in rats
to further investigate whether knocking down EGFR would prevent the progression of PCO in vivo.
Results: The cell proliferation of EGFR siRNA group was apparently inhibited no matter in short or long term and cell
cycle was arrested in G1 phase. Over expression EGF cannot rescue the inhibition of EGFR siRNA on HLE cells and the
proliferation activity in HLE cells greatly decreased when EGF-EGFR signal pathway blockaded. In vivo experiments,
the extent of PCO of EGFR siRNA group is much lower than the control group.
Conclusions: Our results demonstrate that EGFR siRNA can effectively inhibit the progression of PCO. Thus, siRNA
targeting EGFR may provide a totally new way for preventing PCO or even cataract.
Posterior  capsule  opacification  (PCO)  is  the  most
frequent  complication  and  the  primary  reason  of  visual
decrease  after  extracapsular  cataract  surgery.  While  most
patients benefit from this treatment initially, within 5 years of
surgery about 20%–40% suffers a secondary loss of vision
because of posterior capsule opacification (PCO), also known
as after-cataract [1].
Because the residual lens epithelial cells at the equator
and under the anterior lens capsule proliferate and migrate
onto  the  posterior  capsule  and  undergo  epitheliale-
mesenchymal transition (EMT). This results in the formation
of fibroblasts and myofibroblasts, as well as the formation of
extracellular cell matrix (ECM), and finally, the PCO [2-4].
Epidermal growth factor (EGF) is a growth factor that
plays  an  important  role  in  the  regulation  of  cell  growth,
proliferation, and differentiation by binding to its receptor
EGFR. The epidermal growth factor receptor is a member of
the ErbB family of receptors, a subfamily of four closely
related  receptor  tyrosine  kinases:  EGFR  (ErbB-1),  Her2
(human epidermal growth factor receptor 2)/c-neu (ErbB-2),
Her 3 (ErbB-3) and Her 4 (ErbB-4) [5]. Mutations that lead
to EGFR overexpression or over activity have been associated
with several cancers [6]. Especially, mutations, amplifications
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or mis-regulations of EGFR or family members are implicated
in about 30% of all epithelial cancers [7]. Some factors such
as injury may enhance the expression of EGFR [8].
The  present  study  was  undertaken  to  investigate  the
hypothesis that EGFR exerts a critical role on PCO formation
by promoting the survival of abnormal cells with PCO-like
characteristics and the blockage of expression of EGFR in
HLE cells may reduce the development of PCO.
METHODS
Cell  culture:  HLE  cells  were  purchased  from  the  ATCC
(Manassas,  VA),  grown  in  RPMI-1640  culture  medium,
supplemented with 20% premium FBS, 50 U/ml of penicillin,
50 μg/ml streptomycin, and 50 μg/ml gentamycin. Cells were
maintained in a humidified 37 °C atmosphere of ambient air/
5% CO2.
The construction of siRNA expression system: To construct
the siRNA expression vector of EGFR (pSilencer-EGFR), a
74  bp  double  strand  si-EGFR  was  obtained  by  annealing
single strand EGFR-Top line, 5′-GGA TCC CGT GGA GCG
AAT TCC TTT GGA ATT CAA GAG ATT CCA AAG GAA
TTC  GCT  CCA  CTT  TTT  TGG  AAA  AGC  TT-3′;  and
EGFR-Bottom  line,  5′-AAG  CTT  TTC  CAA  AAA  AGT
GGA GCG AAT TCC TTT GGA ATC TCT TGA ATT CCA
AAG GAA TTC GCT CCA CGG GAT CC-3′; Then the
double  strand  was  cloned  into  vector  pSilencer  2.1-neo
(Ambion, Austin, TX). Annealing was performed as: 95 °C
for 5 min and room temperature 2 h.
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2349SiRNA  transfection:  Transient  transfection  of  siRNA
expression  vectors  was  performed  using  Lipofectamine
transfection  reagent  2000  (Invitrogen,  Carlsbad,  CA),
according to the manufacturer’s protocol. HLE cells (5×105
cells per well) were seeded in a 24-well plate or 1.5×106 cells
were seeded in 25 ml culture flask. After 16 h at about 60%
confluence,  the  cells  were  transfected  with  EGFR  siRNA
(1 μg/well, 4 ×g/flask). Four h after transfection, full culture
medium, without antibiotics, was added.
MTT assay: HLE cells (8,000 cell/well) in logarithmic growth
phase  were  cultured  in  96-well  flat-bottomed  plates  in  a
triplicate pattern. Forty-eight h after transfection, 20 μl 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide
(MTT) solution (5 mg/ml) was added to each well which have
already contained 100 μl culture media and incubated for 4 h
at 37 °C. Then 200 μl of DMSO was added to each well and
the plate was vortexed for 10 min at 37 °C. Finally, the optical
density value of each well was measured at 570 nm.
Cell  growth  curve  assay:  To  determine  the  proliferative
ability of cells, 3×104 cells were plated in 24-well plates (three
replicates for each time point), and the number of cells was
counted  everyday  after  plating.  The  growth  assay  was
performed over a period of 8 days, at which time the cells were
confluent.
Cell cycle assay: Cells (1×106) were plated in 60 mm culture
dishes. After an overnight incubation for the cells to adhere,
cells  were  treated  with  EGFR  siRNA  and  non-silencing
siRNA. After incubation for 48 h, the cells were then washed
twice with cold phosphate buffered saline (PBS), detached
with  0.25%  trypsin-EDTA  and  pelleted.  The  pellet  was
suspended in cold PBS and the cells were fixed in a final
concentration of 70% ethanol for 1 h at 4 °C. The cells were
washed with cold PBS and incubated with 100 μg/ml RNase
A for 15 min at 37 °C. Nuclei were stained with 50 mg/ml
propidium iodide (PI; Sigma-Aldrich, St. Louis, MO) for 30
min at 37 °C in the dark. Samples were analyzed by flow
cytometry.  For  flow  cytometric  evaluation  of  cell  cycle,
10,000  events  corrected  for  debris  and  aggregate  were
analyzed for each sample. The proliferation index (PI) was
calculated  as  follows:  PI=(S+G2)/G1.The  assay  was
performed in three replicates.
Real-time PCR: Forty-eight h after transfection, total RNA
was  extracted.  Total  mRNAs  were  reverse  transcribed  by
oligodT primers. The housekeeping gene β-actin (ACTB) was
considered as an endogenous control target gene and controls
were treated with the same conditions and analyzed by real-
time PCR. Real-time PCR was performed as described in the
method of SYBR pre-Mix kits (TakaRa, Dalian, China).
Western blot: Forty-eight h after transfection, HLE cells were
treated with radio immunoprecipitation assay (RIPA) lysis
buffer  containing  1%  protease  inhibitors  (Roche,  Basel,
Switzerland) and proteins were harvested. Equal amounts of
protein were electrophoresed on a 10% SDS–PAGE gel and
then  electro  transferred  to  a  nitrocellulose  membrane
(Millipore, Bedford, MA). The membrane was blocked with
5% nonfat milk for 2 h. Then the membranes were incubated
with  rabbit  anti-human  EGFR  (1:200;  Santa  Cruz
Biotechnology,  Santa  Cruz,  CA)  or  GAPDH  antibody
(1:1000;  Santa  Cruz  Biotechnology)  in  5%  nonfat  milk
overnight, respectively. The membranes were incubated by a
goat anti-rabbit antibody (1:1000; Santa Cruz Biotechnology)
for  90  min  at  room  temperature.  Protein  expression  was
assessed by enhanced chemiluminescence and exposure to
chemiluminescent film.
Aminal experiment, siRNA transfection in vivo: Forty-eight
Sprague Dawley (SD) rats were provided by Tianjin medical
university, Tianjin, China, animal center. All studies were
performed in accordance with the ARVO Statement for the
Use of Animals in Ophthalmic and Vision Research and all
animal  research  protocols  were  approved  by  the  Tianjin
Medical University for Comparative Medicine. The right eye
of each rat was operated for extracapsluar cataract extraction
in all the animals and the rats were divided into 2 groups at
random. Abdominal injection of Aminazine (25 mg/kg) and
Ketamine (50 mg/kg) was used for general anesthesia. After
routine preoperation preparation, make a incision in the clear
cornea with 15° paracentesis knife. After injecting Healon,
make a 3–3.5 mm anterior continue circular capsulotomy with
discission needle, then enlarge the corneal incision to 120°
parallel corneal limbus, revolve lens nucleus into anterior
chamber  after  water  separation  with  BSS  (balanced  salt
solution) and extract it, then aspirate the residual cortex and
irrigate anterior chamber with BSS. Close the incision with
10–0 nylon. Then injected 100 μl transfection mixture into
each  capsule  bag.  The  control  group  was  given  plasmid
pSilencer 2.1 (5 μg), and the siRNA group was treated with
pSilencer-EGFR (5 μg). Eight rats from each group were
separately sacrificed at 1, 7, and 14 days after surgery and 4
eyes were enucleated and processed for light microscopy and
histology analysis, and the other 4 lens capsules were prepared
for western-blot.
Histology: For paraffin embedded samples, each tissue was
sectioned (6 μm) serially perpendicular to the lens capsule and
slides was stained with hematoxylin and eosin. The slides
were observed under microscope and photographed. Then two
slides of each group at each time point were selected to count
the number of cells. Cells in 9 random fields of view at 200×
magnification were counted and expressed as the average
number of cells/field of view. All assays were performed in
triplicate.
Statistical analysis: Data are expressed as the mean±standard
deviation  (SD),  and  a  p<0.05  was  considered  statistically
significant by the Students-Newman-Keuls test.
RESULTS
SiRNA significantly knock downed the expression of EGFR:
To  test  the  efficiency  of  siRNA,  the  constructed  siRNA
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2350expression vector was transfected into HLE cells. After 48 h,
total RNA and protein were extracted from the cells, and then
Real-time and western-blot were applied to test the changes
of EGFR expression. From Figure 1, the results suggested that
the expression of EGFR on both the RNA and protein level
were effectively suppressed by siRNA. EGFR siRNA treated
group was only 45 percent on RNA level and 10 percent on
protein level of the control group which is treated with non-
silencing siRNA.
The effect of siRNA on HLE cell growth: Since the siRNA can
obviously knockdown the expression of EGFR, we intended
to determined whether it can affect the growth ability of HLE
cells. MTT and cell growth curve assay were used to test the
changes of cell growth ability in short-term and long-term
culture,  respectively  (Figure  2).  From  the  figure,  we  can
determine that no matter whether short-term or long-term
culture was used, the proliferation of cells in the siRNA group
was largely suppressed when compared to the control group.
This tendency became more apparent as time increased.
SiRNA of EGFR arrested the G1 phase transition: To explore
whether the inhibition of HLE cells growth was due to the
alteration  in  cell  cycle  progression,  we  performed
fluorescence-activated  cell  sorting  (FACS)  analysis.
Interestingly,  in  the  EGFR  siRNA  treated  group,  the
percentage  of  cells  in  G1  phase  increased  to  41.6%,  as
compared to the control, which had only 29.5% of cells in
G1 phase. The percentage of EGFR siRNA cells in G2 phase
decreased to 27.5%, as compared to 43.7% in the control
group (Figure 3). The proliferation index of EGFR siRNA
treated cells was 140.4% as compared to 239.0% in controls.
These results indicate that EGFR plays an important role in
the transition of the cell cycle and affecting the growth of HLE
cells.
Figure 1. SiRNA significantly knock downed the expression of EGFR in HLE cells. A: Real-time PCR was performed to detect the EGFR
level in HLE cells treated with EGFR siRNA or non-silencing control siRNA. B: Western-Blot was also performed to detect the EGFR level
in these two groups. p<0.05.
Figure 2. MTT and growth curve array was used to determine the effect of EGFR siRNA on HLE cell proliferation activity. p<0.05.
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2351The  role  of  EGF-EGFR  signaling  pathway  in  HLE  cell
proliferation:  Since  EGFR  plays  a  critical  role  in  the
proliferation of epidermal cells, we tested the extent of the
affect on growth characteristics of HLE cells. We used three
different EGF concentrations to treat cells and observed their
effects  on  cells  growth.  From  Figure  4,  we  can  make  a
conclusion that in a certain range, the proliferation ability of
cells is rising following the increase of EGF concentration,
but if the range was exceeded, it may exert an opposing effect.
We choose the most adaptable concentration of recombinant
EGF (10 ng/ml) to simulate the stimulus by overexpressing
EGF to further examine the effect of siRNA.
Compared to the control group, it can be said that the
EGFR siRNA group was almost unchanged when co-supplied
with EGF (Figure 5). Therefore, in this step, we confirmed
that even spurred by EGF, siRNA of EGFR can stably inhibit
the growth of HLE cells in vitro.
In vivo siRNA efficiently inhibits the progression of PCO:
Finally, we investigated the inhibition of EGFR siRNA on
PCO progression in vivo. From Figure 6A,B, although we can
see that the number of HLE cells increased in both groups, the
increase of the control group is more than twice as that of
EGFR siRNA treated group. And the gap between two groups
became more and more obvious as time increased.
Figure 3. Cell cycle test was applied to
check whether EGFR siRNA affect the
proliferation of HLE cells by arresting
the cell cycle. Cells treated with siRNA
of  EGFR  were  G1  phase  arrested.
p<0.05.
Figure  4.  Selecting  a  most  suitable
concentration  of  EGF  for  HLE  cells
growth. p<0.05.
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2352As for the increase of cells in the siRNA group, probably
poor transfection efficiency in vivo is responsible. In Figure
7,  the  result  of  western  blot  shows  that  the  knockdown
efficiency  of  EGFR  is  about  40%  when  compared  to  the
control group, which is lower than in vitro. So we believe that
if we can find a new way to enhance the efficiency of EGFR,
better results will be available.
DISCUSSION
PCO puts a great threat on maintaining normal visual function
after cataract surgery [9,10]. The incidence of PCO is 30%–
50% in adult, and 100% in children [11]. Though the reason
of PCO has been known for some time, the mechanism of it
is yet not clearly understood. A large number of studies have
been taken to explore an efficient way for getting rid of this
complication.
The EGFR signaling pathway has an important role in
cell proliferation, especially epithelial cells. Many diseases
have been reported to be closely related with the deregulation
of EGFR signaling [12-14].
After  activated  by  binding  of  its  specific  ligands,
including epidermal growth factor and transforming growth
factor α (TGF-α), EGFR can stimulate the intrinsic protein-
tyrosine kinase activity of the receptor. The tyrosine kinase
activity, in turn, initiates a signal transduction cascade that
results in a variety of biochemical changes within the cell – a
Figure 5. Using the selected concentration of EGF to further test the inhibitory effect of EGFR siRNA on cells. MTT and growth curve array
were applied. Compared to the control group, it can be seen that the EGFR siRNA group was almost unchanged when co-supplied with EGF.
p<0.05.
Figure 6. In vivo experiments demonstrated that siRNA of EGFR can efficiently inhibit the progression of PCO. A: The cell number of HLE.
Cells in 9 random fields of view at 200×magnification were counted and expressed as the average number of cells/field of view, p<0.05. B:
Slides were stained with hematoxylin and eosin.
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2353rise in intracellular calcium levels, increased glycolysis and
protein synthesis, and increases in the expression of certain
genes including EGFR – that ultimately lead to DNA synthesis
and cell proliferation [15].
In our study, we hypothesized that EGFR has a vital role
in  the  process  of  PCO.  The  morphological  and  immune
properties of eyes make it suitable for RNAi treatment [16].
So we used RNAi and designed a series of experiments in vitro
or in vivo to test our assumption.
The  results  of  MTT  and  cells  growth  curve  assay  is
surprisingly similar in that EGFR siRNA can stably suppress
the proliferation of HLE cells, with or without the stimulus of
EGF. And in vivo experiments, we directly gave a transfection
mixture to the capsular bag of rats immediately after surgery.
Maybe transfection efficiency was much lower than in vitro,
but even so, the proliferation of HLE cells in the bag was
significantly inhibited by siRNA. Based on these results, we
probably  can  make  such  a  conclusion  that  EGFR  is  an
effective  target  of  PCO,  and  siRNA  of  EGFR  can  be  a
potential drug for preventing it.
However,  this  study  may  not  completely  remove  the
problem of PCO. First of all, HLE cells also express other
various  kinds  of  growth  factors  and  receptors  in  the  cell
membrane,  and  these  growth  factor  and  its  receptors
composing signaling pathway can enhance the proliferation,
differentiation,  and  collagen  fiber  excretion  [17].  For
example, TGF-β was reported in many articles to be closely
related with HLE cells [18-23].
Second, as we can see from the data of our studies, the
efficiency  of  siRNA  in  vivo  is  not  as  high  as  in  vitro
experiments. So, if we can enhance the transfection efficiency
of siRNA in vivo, we believe that a much satisfying result
could be obtained. Perhaps the Lentiviral expression system
could be applied to infect HLE cells in capsular bag to get
desirable results.
Figure 7. Western-blot tests the inhibitory effect of EGFR siRNA in
vivo on HLE cells. p<0.05.
In summary, siRNA of EGFR seems to be a potential
therapy of PCO which might be developed into a drug in the
future. And due to the instability of transient transfection, a
virus expression system may provide an effective solving
solution.
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